Xigris can help organs get back to work and improves survival
Welcome to Xigris.com, your online source for information about sepsis and the role of Xigris® (drotrecogin alfa [activated]) in the treatment of adult high-risk severe sepsis patients.
Sepsis is a common, deadly, and underdiagnosed disease that causes approximately 1400 deaths worldwide each day.1 Sepsis can develop as a complication after common illnesses such as pneumonia and bacterial infections.
In high-risk severe sepsis (sepsis associated with acute organ dysfunction), Xigris helps you save more lives. When cardiovascular, renal, or respiratory dysfunction occurs in severe sepsis, Xigris has been shown to help.
Xigris is indicated for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death (eg, as determined by APACHE II*).
Xigris is not indicated in adult patients with severe sepsis and lower risk of death. Xigris is not indicated in pediatric patients with severe sepsis.
Of measures used in the PROWESS† clinical trial, the APACHE II score was most effective in classifying patients by risk of death and by likelihood of benefit from Xigris.
Unless otherwise noted, Xigris and standard therapy data presented here represent high-risk (APACHE II ≥25) patients from the PROWESS clinical trial.
*APACHE (Acute Physiology And Chronic Health Evaluation). For more information on using the APACHE II scoring system, please see http://www.sfar.org/scores2/scores2.html.
†Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.
Reference:
1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655.
Bleeding is the most common adverse reaction associated with Xigris therapy. Please see Important Safety Information.
